• Publications
  • Influence
Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer
TLDR
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone‐receptor–positive, HER2‐negative, axillary node–negative breast cancer who had a midrange 21‐gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger.
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
TLDR
Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
TLDR
Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone.
Integrated digital error suppression for improved detection of circulating tumor DNA
TLDR
This work introduces an approach for integrated digital error suppression (iDES), which combines in silico elimination of highly stereotypical background artifacts with a molecular barcoding strategy for the efficient recovery of cfDNA molecules, and facilitates noninvasive variant detection across hundreds of kilobases of circulating tumor DNA.
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth
TLDR
Since ER inhibits the constitutive as well as inducible activation function of NF-kappaB in a dose-dependent manner, it is proposed that breast cancers that lack functional ER overexpress NF- kappaB-regulated genes.
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
TLDR
F. Cardoso*, E. Senkus, A. Papadopoulos, M. Mayer, G. Vorobiof, B. Thomssen, D. Spence, C. Norton & E. Winer.
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
TLDR
Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastzumab significantly improved PFS and CBR versus lapatinIB alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
TLDR
The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable, and these data support the initiation of trials in metastatic breast cancer combining bevacszumab with chemotherapy.
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
TLDR
Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of > or = 0.3 mg/kg have a half-life similar to that of other humanized antibodies.
...
1
2
3
4
5
...